{"filings":[{"id":1224596,"accession_number":"0001193125-26-279788","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-06-23T21:19:36+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tango Therapeutics appoints Robert Azelby to board; receives option for 35,910 shares at $27.97","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to seven directors; Azelby fills newly created vacancy as Class II director term expiring 2029.","Azelby is independent; will serve on Compensation and Nominating/Corporate Governance committees.","Receives equity: option to purchase 35,910 shares at $27.97, plus RSU for 5,740 shares, vesting over 3 years.","Annual retainer of $45,000 for board service plus committee retainers of $7,500 and $5,000.","Azelby brings 30+ years biopharma experience including Juno and Amgen; company advancing vopimetostat for pancreatic cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":975277,"accession_number":"0001193125-26-266078","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-06-10T21:22:21+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tango Therapeutics raises ~$566.5M in public offering to fund R&D and commercialization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 18,166,667 shares at $30.00/share and pre-funded warrants for 1,833,395 shares at $29.999/warrant.","Net proceeds expected ~$566.5M after underwriting discounts and expenses; closing expected June 11, 2026.","Proceeds for R&D, pivotal trial, potential commercialization, G&A, and capex; cash runway extended into 2030.","Underwriters granted 30-day option to purchase up to 3,000,009 additional shares at public offering price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":900238,"accession_number":"0001193125-26-260679","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-06-08T11:15:55+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tango reports 92% ORR in PDAC with vopimetostat + daraxonrasib combo; plans Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["92% ORR (11/12) in PDAC with vopimetostat + daraxonrasib; 90% 6-month PFS; 100% DCR.","100% ORR (3/3) in NSCLC with same combination; all responses confirmed.","Vopimetostat + zoldonrasib showed 52% ORR (14/27) in PDAC; 74% 6-month PFS; 96% DCR.","Combinations well tolerated; no discontinuations due to AEs; no Grade 4/5 related AEs.","Company plans Phase 3 randomized-controlled trial in front-line pancreatic cancer in 2H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":863437,"accession_number":"0001193125-26-257760","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-06-04T21:19:05+00:00","items":["5.07"],"status":"ready","headline":"Tango Therapeutics annual meeting elects two Class II directors, ratifies auditor, approves NEO compensation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Peters elected with 98,188,796 for; 17,623,596 withheld; Rothenberg with 92,476,172 for; 23,336,220 withheld.","Ratification of PricewaterhouseCoopers as 2026 auditor: 131,097,992 for, 73,823 against, 26,266 abstain.","Advisory vote on named executive officer compensation: 113,915,877 for, 1,855,838 against, 40,677 abstain.","Director Kanishka Pothula resigned effective May 13, 2026 prior to meeting; not a disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68483,"accession_number":"0001193125-26-221677","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-05-13T20:16:36+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q1 net loss $45.5M; cash $379.8M; board resignations; vopimetostat combo data due 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $45.5M ($0.32/sh) vs $39.9M ($0.36/sh) YoY; R&D $33.5M, G&A $15.2M.","Cash $379.8M as of March 31, 2026; runway into 2028.","Directors Alexis Borisy and Kanishka Pothula resigned May 13; Sung Lee takes Lead Independent Director and Compensation Chair.","Initial phase 1/2 data for vopimetostat + RAS(ON) inhibitors expected in 2026; registrational path being reviewed.","New leadership appointments: Matthew Gall as CFO, Yen-Ching Chua as CDOO, Janice Kapty as SVP Corp Strategy (April 2026)."],"consensus_eps_estimate":-0.3196,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95758,"accession_number":"0001193125-26-213491","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tango Therapeutics CFO Daniella Beckman Separates; Severance Includes 12-Month Pay, Equity Acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Daniella Beckman ceased serving as principal financial officer effective April 15, 2026.","Separation agreement provides 12 months severance at current base salary paid over 12 months.","Company accelerates vesting of equity awards that would have vested in 24 months following May 1, 2026.","Vested stock options exercise period extended through August 31, 2026.","Beckman executed a general release in favor of the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95757,"accession_number":"0001193125-26-156127","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tango Therapeutics appoints new CFO, additional execs to accelerate vopimetostat development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniella Beckman departs as CFO effective April 15; Matthew Gall named successor.","Matthew Gall receives $540K base salary, 40% target bonus, 240K option shares, 40K RSUs.","Jessica Newcomb appointed principal accounting officer; Yen-Ching Chua named Chief Development Operations Officer.","Janice Kapty named SVP Corporate Strategy and Project Leadership; company focuses on vopimetostat for pancreatic cancer.","Tango plans to present key clinical data in 2026, including combination trial with Revolution Medicines' RAS(ON) inhibitors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109054,"accession_number":"0001193125-26-092535","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics reports Q4 net loss $38.7M, cash $343M; vopimetostat pivotal study on track for 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.7M for Q4 2025 ($0.29/share) vs $30.8M for Q4 2024; FY2025 net loss $101.6M vs $130.3M.","Cash, equivalents and marketable securities $343.1M as of Dec 31, 2025; runway into 2028.","Collaboration revenue $62.4M for FY2025, including full recognition of remaining Gilead deferred revenue after collaboration truncation.","Vopimetostat pivotal study in 2L MTAP-del pancreatic cancer to start in 2026; initial phase 1/2 combo data with RAS(ON) inhibitors expected in 2026.","Signed clinical supply agreement with Erasca for vopimetostat + pan-RAS molecular glue ERAS-0015; CEO succeeded by Malte Peters in January 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109053,"accession_number":"0001193125-26-007086","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Tango Therapeutics appoints Malte Peters CEO as founder Barbara Weber becomes Executive Chair; cash $343M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Barbara Weber, M.D. retires as President and CEO effective Jan 8, 2026; becomes Executive Chair through 2026.","Malte Peters, M.D., board member since 2018, named President and CEO; granted 1.65M options and 350K RSUs.","Cash, cash equivalents and marketable securities totaled $343M as of Dec 31, 2025 (unaudited).","2026 milestones reiterated: vopimetostat combos data, lung cancer update, pancreatic pivotal start, TNG456 data.","Alexis Borisy transitions from Board Chair to Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109052,"accession_number":"0001193125-26-001495","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Tango Therapeutics appoints Sung H. Lee to Board; grants option for 60k shares at $8.93","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to 8; Lee appointed as Class I director, term until 2028 annual meeting.","Lee to receive stock option for 60,000 shares at $8.93, vesting monthly over 3 years.","Lee to receive RSU for 10,000 shares vesting annually over 3 years; $40k annual retainer.","Lee is EVP & CFO at Cytokinetics, previously CFO at Vir, MorphoSys, Sangamo; 20+ yrs finance experience.","CEO says Lee's expertise will support lead program vopimetostat in registrational studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125521,"accession_number":"0001193125-25-290679","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Tango Therapeutics enters $100M ATM offering with Leerink, terminates Jefferies ATM program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $100M at-the-market common stock sales agreement with Leerink Partners as agent, dated Nov 21, 2025.","Agent commission of up to 3.0% of gross sales price per share sold under the agreement.","Prior $100M Jefferies ATM program terminated effective Nov 21, 2025, with no penalties.","Shares to be sold via at-the-market or negotiated transactions at company's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125520,"accession_number":"0001193125-25-263684","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q3 2025 net income $15.9M; vopimetostat mPFS 7.2 mo in pancreatic; cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $15.9M ($0.14 basic EPS) vs net loss $29.2M in Q3 2024; nine-month net loss $62.8M.","Collaboration revenue $53.8M (Q3 2024: $11.6M) as Gilead collaboration truncated; all deferred revenue recognized.","Vopimetostat in 2L MTAP-del pancreatic cancer showed median PFS 7.2 months; 49% ORR and mPFS 9.1 mo in histology-selective cohort.","October 2025 financing raised $225M gross ($212M net); cash, equivalents and marketables $152.8M as of Sept 30, extending runway into 2028.","TNG456 granted Orphan Drug Designation for malignant glioma; pivotal pancreatic study for vopimetostat anticipated to start 2026."],"consensus_eps_estimate":-0.0538,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":62384000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125519,"accession_number":"0001193125-25-249302","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Tango Therapeutics raises ~$212M via registered direct offering and PIPE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 21.0M shares and 3.2M pre-funded warrants at $8.66; net proceeds ~$197M.","Separate PIPE of 1.7M shares at $8.66 for ~$15M total gross proceeds.","Proceeds to advance pipeline and general corporate purposes; cash runway extended into 2028.","Closings expected October 24, 2025; customary conditions apply.","Officers and directors to enter 60-day lock-up agreements per PIPE terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125518,"accession_number":"0001193125-25-247658","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Tango Therapeutics discloses $152.8M cash; provides vopimetostat clinical update","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Estimated cash, cash equivalents, and marketable securities of $152.8M as of Sept 30, 2025 (preliminary, unaudited).","Clinical slide presentation on ongoing Phase 1/2 trial of vopimetostat (TNG462) made available on Oct 23, 2025.","Cash estimate subject to completion of financial closing procedures and may change materially; auditor has not reviewed.","No full financial results or specific clinical data included in the disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142255,"accession_number":"0001193125-25-187680","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Douglas Barry resigns as Chief Legal Officer and Corporate Secretary of Tango Therapeutics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Barry resigned as Chief Legal and Compliance Officer and Corporate Secretary effective September 12, 2025.","No replacement named; Barry departing to pursue another opportunity.","Resignation covers both officer and corporate secretary roles simultaneously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142254,"accession_number":"0000950170-25-102387","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q2 net loss $38.9M ($0.35/sh); Gilead collab truncated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.9M ($0.35 per share) vs $25.6M ($0.24) in Q2 2024; revenue fell to $3.2M.","Cash $180.8M; expects to fund operations into Q1 2027.","Gilead collaboration research term trimmed from 7 to 5 yrs; $53.8M deferred revenue to be recognized in Q3 2025.","First patients dosed in TNG462 combo with Revolution Medicines RAS(ON) inhibitors and TNG456 Phase 1/2.","TNG462 monotherapy data expected 2H 2025; TNG260 clinical data also expected 2H 2025."],"consensus_eps_estimate":-0.3548,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":8573000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160265,"accession_number":"0001193125-25-137032","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tango Therapeutics shareholders approve doubling authorized shares to 400M, elect new director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to increase authorized common stock from 200M to 400M shares (85.8M for, 11M against).","Lesley Ann Calhoun elected as Class I director with 73.1M votes for, 10.5M withheld.","Ratification of PricewaterhouseCoopers as auditor for FY2025 passed with 96.7M for.","Non-binding say-on-pay passed; annual advisory vote frequency approved (73M votes for one year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160264,"accession_number":"0000950170-25-068546","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q1 net loss $39.9M; cash runway extended to Q1 2027; TNG462 data update 2H2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $39.9M ($0.36/share) for Q1 2025 vs $37.9M ($0.35/share) in Q1 2024.","Cash of $216.7M; runway extended into Q1 2027 via reduction in preclinical spend and headcount.","TNG462 Phase 1/2 monotherapy data update expected 2H 2025; registrational study in pancreatic cancer planned for 2026.","Combination trial of TNG462 with Revolution Medicines' RAS(ON) inhibitors daraxonrasib and zoldonrasib to begin enrollment Q2 2025.","TNG456 Phase 1/2 trial for glioblastoma enrollment expected Q2 2025; TNG260 clinical data update expected 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":5392000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178561,"accession_number":"0000950170-25-028345","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics reports Q4 2024 net loss of $37.7M; cash runway into 3Q 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.7M for Q4 2024 ($0.35 per share) vs $30.8M loss in Q4 2023; full year net loss $130.3M ($1.19 per share).","Cash and marketable securities $257.9M as of Dec 31, 2024; expected to fund operations into 3Q 2026.","TNG462 granted FDA Orphan Drug Designation for pancreatic cancer; Phase 1/2 data update expected in 2025.","IND for TNG456 cleared; Phase 1/2 enrollment expected 1H 2025; clinical collaboration with Lilly for abemaciclib combination.","TNG260 proof-of-mechanism established; dose expansion ongoing in lung cancer; clinical update expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":42069000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178560,"accession_number":"0001193125-25-004977","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tango Therapeutics discloses $257.9M cash as of Dec 31, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities totaled $257.9M (unaudited).","Company updated its corporate presentation for use with investors and analysts.","No other financial results or guidance were provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195228,"accession_number":"0000950170-24-121810","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Tango reports Q3 loss $29.2M; TNG462 shows durable activity; PRMT5 program advanced","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["TNG462 demonstrated clinical activity across multiple tumor types; 43% ORR in cholangiocarcinoma (n=7); median time on treatment 24 weeks and increasing.","Multiple TNG462 combos planned 1H 2025 with RAS(ON) inhibitors (Revolution Medicines), osimertinib, and pembrolizumab.","TNG908 enrollment stopped due to insufficient CNS exposure in glioblastoma; next-gen brain-penetrant TNG456 enters phase 1/2 1H 2025.","Cash $293M as of Sept 30, 2024; cash runway into 3Q 2026; Q3 net loss $29.2M ($0.27/shr) vs $22.3M ($0.23/shr) year ago.","Maeve Waldron-Lynch, M.D. joins as SVP Head of Clinical Development, bringing late-stage oncology regulatory experience."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":37952000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211482,"accession_number":"0000950170-24-092270","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q2 2024 net loss $25.6M; cash $322M, runway to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.6M ($0.24/share) vs $20.7M loss ($0.23/share) in Q2 2023.","Collaboration revenue $7.8M, down from $9.6M YoY; license revenue $12.1M (incl. $12M Gilead fee).","R&D expenses $38.7M, up from $28.7M YoY due to clinical program advancement.","Cash, equivalents and marketable securities $322.1M; expected to fund operations into 2027.","PRMT5 program (TNG908/TNG462) dose expansion ongoing; comprehensive data update expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":26346000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230143,"accession_number":"0001193125-24-156048","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Tango Therapeutics stockholders approve officer liability limit and elect directors at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to Second Amended and Restated Certificate of Incorporation to limit officer liability under Delaware law (89.9M for, 5.5M against).","Elected Alexis Borisy, John Ketchum, and Barbara Weber as Class III directors each with >90M votes for.","Ratified PricewaterhouseCoopers as independent auditor for FY2024 (100.7M for, 2K against).","Quorum of 94.35% (100.7M shares) present at virtual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230142,"accession_number":"0001193125-24-145434","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Tango Therapeutics discontinues TNG348 program due to liver toxicity in phase 1/2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2 trial of TNG348, a USP1 inhibitor, terminated because of Grade 3/4 liver function abnormalities in patients on study >8 weeks.","No patient had received TNG348 in combination with olaparib; single-agent toxicity drove decision.","Cash runway extended into 2027; PRMT5 (TNG908/TNG462) and CoREST programs remain on track with clinical update expected H2 2024.","CEO Barbara Weber cited patient safety as priority; stock may react to loss of pipeline candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230141,"accession_number":"0000950170-24-055062","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.","Cash, equivalents and marketable securities of $343.6M as of March 31, 2024.","R&D expense rose to $38.1M from $28.0M due to clinical program advancement.","Dose expansion initiated for TNG908 (PRMT5 inhibitor) in MTAP-deleted tumors.","PRMT5 clinical data update expected in 2H 2024; TNG462 expansion expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":6471000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248576,"accession_number":"0000950170-24-032513","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q4 2023 net loss $30.8M; cash $336.9M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $30.8M ($0.32/sh); full year net loss $101.7M ($1.08/sh).","Cash $336.9M at Dec 31, 2023; plus $41.7M from Jan 2024 ATM; runway into late 2026.","Four phase 1/2 trials ongoing; TNG908 clinical data expected 2024; first patient dosed for TNG348.","FDA Orphan Drug Designation granted for TNG462 for soft tissue sarcomas.","Appointed Chief Regulatory Officer, Chief Development Operations Officer, Chief Legal Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248575,"accession_number":"0001193125-24-025907","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Tango Therapeutics reports $337M cash, $42M ATM proceeds, runway into late-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, cash equivalents and marketable securities at Dec 31, 2023: $337M (unaudited).","Net proceeds of $42M from at-the-market offering completed in January 2024.","Company estimates sufficient cash to fund operations into late-2026.","Figures are preliminary and subject to completion of financial closing procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266076,"accession_number":"0000950170-23-060671","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Q3 net loss $22.3M; cash $360M into 2026; TNG348 Fast Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $359.9M at Sept 30, 2023; runway into 2026.","Net loss $22.3M ($0.23/share) vs $29.1M ($0.33/share) in Q3 2022; net loss $71.0M YTD.","TNG348 (USP1 inhibitor) granted FDA Fast Track for BRCA1/2-mutant cancers; IND cleared; phase 1/2 start expected H1 2024.","TNG908 (PRMT5) dose escalation ongoing; additional clinical data expected in 2024.","Kanishka Pothula appointed to Board; Jannik Andersen promoted to CSO; $80M private placement closed in August 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":31096000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283303,"accession_number":"0001193125-23-224253","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2023-08-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tango Therapeutics director Aaron Davis resigns; John Ketchum appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aaron Davis resigned from board effective Aug 28, 2023; no disagreement with management.","John Ketchum appointed as Class III director effective Aug 29, 2023; will stand for election at 2024 annual meeting.","Ketchum receives option for 60,000 shares at $7.19, RSU for 10,000 shares, and $40k annual retainer.","Ketchum deemed independent under Nasdaq rules; no committee assignments yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283302,"accession_number":"0001193125-23-208100","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Tango Therapeutics raises $80M in PIPE financing at $5.15 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$80M from sale of ~15.5M shares/pre-funded warrants at $5.15/share.","Financing led by Nextech, with participation from Boxer Capital, Bain Capital Life Sciences, Casdin Capital, EcoR1 Capital, Southpoint Capital, Third Rock Ventures, and a large institutional investor.","Proceeds expected to fund operations into 2026; extends runway for PRMT5 programs TNG908 and TNG462, and TNG260 trial.","Pre-funded warrants exercisable at $0.0001, immediately exercisable; company to file resale registration statement by Sep 1, 2023.","Directors and officers subject to 90-day lock-up agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283301,"accession_number":"0000950170-23-038742","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Tango doses first patients in TNG462, TNG260 trials; CSO Alan Huang to depart; Q2 net loss narrows","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in phase 1/2 of TNG462 (next-gen PRMT5 inhibitor) for MTAP-deleted tumors.","First patient dosed in phase 1/2 of TNG260 (CoREST inhibitor) with pembrolizumab for STK11-mutant cancers.","CSO Alan Huang to step down Oct 2023; Jannik Andersen promoted to CSO effective Oct 9, 2023.","Cash $310.7M as of June 30, 2023, sufficient to fund operations into 2026.","Q2 2023 net loss $20.7M ($0.23/sh) vs $24.9M ($0.28/sh) in Q2 2022; license revenue $5.0M from Gilead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302740,"accession_number":"0001193125-23-162609","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tango Therapeutics stockholders elect two Class II directors and ratify PwC as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Malte Peters, M.D. elected with 75,943,817 votes for, 3,532,483 withheld (5,145,731 broker non-votes).","Mace Rothenberg, M.D. elected with 76,746,614 votes for, 2,729,682 withheld (5,145,731 broker non-votes).","Ratification of PricewaterhouseCoopers as auditor: 84,619,141 for, 2,888 against, 2 abstain.","Quorum of 95.93% (84,622,031 of 88,209,964 shares) present at virtual annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302739,"accession_number":"0000950170-23-019133","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q1 net loss $0.32/sh; cash $334M funds pipeline into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $28.0M ($0.32 per share) vs $25.2M ($0.29) in prior year; revenue flat at $5.8M.","Cash and equivalents $333.6M; expects to fund operations into 2026.","TNG908 shows proof-of-mechanism with selective PRMT5 inhibition in MTAP-deleted tumors; no DLTs or grade >2 AEs.","FDA cleared IND for TNG260 (CoREST inhibitor) and granted Fast Track designation for STK11-mutant NSCLC; phase 1/2 to start 2H 2023.","Appointed Adam Crystal, M.D., Ph.D., as President of R&D in February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":5766000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322369,"accession_number":"0000950170-23-009852","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics reports Q4 2022 net loss $29.1M; TNG462 gets Fast Track; appoints new R&D President","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.1M in Q4 2022 ($0.33/share) vs $22.0M ($0.25) in Q4 2021; FY2022 net loss $108.2M ($1.23) vs $58.2M ($0.94).","Cash of $366.1M at Dec 31, 2022 expected to fund operations into 2025.","FDA granted Fast Track Designation to TNG462, a next-gen MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers.","Adam Crystal, M.D., Ph.D. appointed President of Research and Development in February 2023.","Upcoming: TNG908 proof-of-mechanism update Q2 2023; IND filings for TNG260 (H1 2023) and TNG348 (mid-2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322368,"accession_number":"0001193125-23-052289","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Tango Therapeutics appoints Adam Crystal as President, R&D; base salary $550k, equity grants","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam Crystal, M.D., Ph.D., appointed President, Research & Development, effective Feb 27, 2023.","Annual base salary of $550,000; one-time sign-on bonus of $275,000 (clawback if leaves before Feb 27, 2024).","Equity grants: stock options for 487,500 shares and RSUs for 81,250 shares, with time-based vesting.","Target annual cash incentive of 45% of base salary; severance includes 12 months salary and COBRA coverage.","Crystal previously CMO at C4 Therapeutics and clinical program leader at Novartis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340424,"accession_number":"0000950170-22-024215","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q3 2022 net loss $29.1M; cash $393.3M; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.1M ($0.33/share) vs $19.6M ($0.28) year ago; cash $393.3M sufficient into 2025.","TNG908 phase 1/2 trial enrolling; CTA approved in France; initial safety and efficacy data expected H1 2023.","Disclosed TNG260 as CoREST inhibitor for STK11-mutant cancers; IND filing on track for H1 2023.","Declared TNG348 development candidate for BRCA1/2-mutant cancers; IND filing planned for 2023.","Appointed Aaron Weitzman as CMO; R&D expenses $28.7M, G&A $8.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":18449000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357688,"accession_number":"0000950170-22-016251","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q2 2022 net loss $24.9M; TNG908 Orphan Drug Designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $416.4M as of June 30, 2022.","Net loss $24.9M ($0.28/share) vs $4.5M ($0.09) in Q2 2021; R&D expense $23.7M vs $19.1M.","TNG908 Phase 1/2 enrolling MTAP-deleted solid tumors; FDA Orphan Drug Designation for MPNST.","TNG462 (45-fold more potent PRMT5 inhibitor) and TNG260 declared development candidates; IND filings expected 1H 2023.","Added to Russell 2000, 3000 and Microcap indexes in June 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":11529000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376288,"accession_number":"0000950170-22-011475","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tango Therapeutics shareholders elect Calhoun and Huber as Class I directors, ratify PwC as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lesley Ann Calhoun elected with 74,549,730 votes for, 2,532,608 withheld, 4,658,458 broker non-votes.","Reid Huber elected with 74,547,606 votes for, 2,534,732 withheld, 4,658,458 broker non-votes.","PricewaterhouseCoopers ratified as independent auditor for FY2022 with 81,737,938 votes for, 400 against, 2,458 abstain.","Annual meeting held June 8, 2022; 81,740,796 shares represented (93.19% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376287,"accession_number":"0000950170-22-009137","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q1 net loss $25.2M; cash $449.9M; TNG908 trial open","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.2M ($0.29/share) vs $12.1M loss in Q1 2021; R&D expense $24.3M (+62% YoY).","Cash, cash equivalents & marketable securities $449.9M; expected to fund operations into H2 2024.","TNG908 Phase 1/2 trial open for MTAP-deleted solid tumors; FDA Fast Track Designation granted.","Declared TNG462 (next-gen PRMT5 inhibitor) and TNG260 (STK11-loss inhibitor) as development candidates.","Collaboration revenue $5.8M, down from $6.4M, due to lower Gilead research costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":5758000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394648,"accession_number":"0001193125-22-085927","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2022-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics reports Q4 2021 net loss $22.0M; cash $485.3M; TNG908 Fast Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2021: $22.0M ($0.25/share) vs $8.9M ($0.22/share) in Q4 2020; full year $58.2M ($0.94/share).","Revenue Q4 2021: $5.7M vs $9.1M in Q4 2020; full year $37.0M vs $7.7M in 2020 (Gilead amendment effect).","Cash, equivalents & marketable securities: $485.3M as of Dec 31, 2021, expected to fund operations into H2 2024.","TNG908 (PRMT5 inhibitor) granted FDA Fast Track; Phase 1/2 trial expected to start Q2 2022.","Target 3 and USP1 development candidates expected Q2 and H2 2022, respectively; leadership team expanded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":413288,"accession_number":"0001193125-21-323744","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tango Therapeutics Q3 2021 net loss $19.6M; cash $503.8M funds into H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.6M ($0.28/share) vs $26.8M ($0.76) in Q3 2020; loss narrowed on revenue change.","Cash, equivalents and marketable securities $503.8M; management expects to fund operations into H2 2024.","Collaboration revenue was $6.8M vs negative $11.3M a year ago, due to Gilead amendment charge in Q3 2020.","TNG908 IND on track for Q4 2021; Phase 1/2 trial initiation expected in H1 2022.","Closed business combination with BCTG Acquisition Corp. and PIPE, yielding gross proceeds of $342M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":31326000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431873,"accession_number":"0001193125-21-246234","cik":1819133,"company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["1.01","2.01","9.01","3.02","3.03","4.01","5.01","5.02","5.03","5.05","5.06","5.07"],"status":"ready","headline":"Tango Therapeutics completes de-SPAC merger; starts trading on Nasdaq under TNGX","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Aug 10, 2021; Old Tango shares converted at ~0.34 share of new common stock per share.","PIPE investors purchased 18.61M shares at $10.00/share, raising $186.1M in gross proceeds.","Post-merger, 87,474,258 shares of common stock outstanding and 9,498,725 shares subject to equity awards.","Common stock began trading on Nasdaq Capital Market on Aug 11, 2021 under ticker TNGX.","Directors and officers entered into lock-up agreements for 180 days after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2885003900.199237,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}